Dr. Kay Discusses the Role of Acalabrutinib in CLL

Neil E. Kay, MD
Published: Friday, Mar 09, 2018



Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) works the same mechanism as ibrutinib (Imbruvica), but has less off-target effects in terms of enzyme targets, says Kay. This means that the toxicity profile of acalabrutinib may be less in some patients than if they were treated with ibrutinib.

Although effective, the major issue with ibrutinib has been the chronic low-grade toxicities such as arthralgia, diarrhea, hypertension, and rash, are problematic for patients. Kay says that many of these toxicities result in patients having to stop treatment with ibrutinib. Acalabrutinib may be a good alternative for these patients.


Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

The Bruton's tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) works the same mechanism as ibrutinib (Imbruvica), but has less off-target effects in terms of enzyme targets, says Kay. This means that the toxicity profile of acalabrutinib may be less in some patients than if they were treated with ibrutinib.

Although effective, the major issue with ibrutinib has been the chronic low-grade toxicities such as arthralgia, diarrhea, hypertension, and rash, are problematic for patients. Kay says that many of these toxicities result in patients having to stop treatment with ibrutinib. Acalabrutinib may be a good alternative for these patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x